Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to assets ratio is 0.00% as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly debt to assets ratio; no daily interpolation. Q4 FY2025 (2025-12-31): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
0.00%
DEBT TO ASSETS RATIO AVG 3Y
0.00%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$215.51M
Debt to Assets Ratio
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$214.42M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$213.19M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$212.75M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.89M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.83M
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$222.46M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$222.75M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $215.51M | 0.00% | 0.00% | 0.00% | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.42M | 0.02% | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.19M | 0.12% | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $212.75M | 0.09% | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.33M | 0.02% | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $208.89M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $208.83M | 0.16% | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $222.46M | 0.05% | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $222.75M | 0.12% | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $207.80M | 0.00% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
344.31
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-06-30 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-06-30 | 0.00% |
| 2022-12-31 | 0.00% |
